Core Insights - Velocity Clinical Research has appointed Andrew (Drew) Reina as Chief Revenue Officer, effective immediately, to enhance its strategic partnerships and revenue growth [1][2][3] Company Overview - Velocity is a leading integrated site organization for clinical trials, operating over 70 sites with more than 200 investigators, partnering with pharmaceutical and biotechnology companies [7] - The company aims to set the standard for strategic relationships between multisite clinical research corporations, Sponsors, and CRO partners [2] Leadership and Experience - Drew Reina brings over two decades of global clinical research experience, previously serving as Vice President and Head of Sales at Fortrea, where he led a high-performing commercial organization [4][5] - His experience includes overseeing a $1 billion+ global portfolio at PPD's Biopharma segment, focusing on strategic partnerships and alliance management [5] Strategic Goals - As CRO, Drew will drive growth through strategic partnerships with Sponsors and CROs, aligning business development, marketing, and network operations to ensure consistent revenue performance [6] - The organization is positioned to meet the evolving needs of clinical research, helping to accelerate speed to market and alleviate burdens on sites and patients [4][6] Technological Advancements - Velocity operates a technology hub in India, developing innovative systems to leverage expansive site, patient, and historical performance data, enhancing efficiency in clinical trials [8]
Velocity Clinical Research Appoints Former Fortrea Executive, Andrew Reina, as Chief Revenue Officer